Should I Wait for Retatrutide? What TRIUMPH-1's 28.3% Phase 3 Readout Just Changed About Obesity Prescribing

A version of this conversation is happening in primary-care offices across the US right now. A 48-year-old patient with a BMI of 34 and pre-diabetes is sitting across from her doctor. She's read the May 21 headlines. Retatrutide just delivered 28.3% mean weight loss in TRIUMPH-1, with 45.3% of participants reaching ≥30% weight loss — bariatric-surgery territory. The NDA filing follows TRIUMPH-2 and TRIUMPH-3 readouts later this year. Her question to her doctor is simple: should I start Wegovy or Zepbound now, or hold out for retatrutide?

The honest answer for most patients is no — don't wait. The reasoning isn't that retatrutide isn't real (the Phase 3 data confirms the Phase 2 efficacy expectation) and it's not that the additional weight loss isn't meaningful (28.3% on 12 mg is the highest mean loss ever recorded in a registrational obesity trial). The reasoning is that 'waiting' in obesity therapeutics is a slower-than-you-think gamble that costs you 18-24 months of weight loss you could have had, accumulates additional cardiovascular and metabolic risk, and gives you a drug that — when it arrives — will probably be priced at $1,500-$2,000/month list with insurance access about as messy as Wegovy's was in 2023.

This piece walks through what TRIUMPH-1 just delivered, what TRIUMPH-2 and TRIUMPH-3 still need to deliver, what the realistic approval and access timeline looks like now that the registrational trial has read out, when waiting actually makes sense, and how to think about the trade-off if you're starting from scratch in late May or June 2026.

Retatrutide (LY3437943) is Lilly's triple-agonist peptide. It binds three receptors simultaneously: GLP-1 (the same receptor that semaglutide and tirzepatide hit), GIP (the second receptor that tirzepatide adds), and glucagon (the third one that's unique to retatrutide among the current top-tier candidates). Each receptor contributes a distinct piece of the metabolic effect: GLP-1 drives appetite suppression and slowed gastric emptying, GIP contributes additional insulin sensitization and fat-mass-selective weight loss, and glucagon raises resting energy expenditure and drives hepatic fatty-acid oxidation.

The net effect: more weight loss than either tirzepatide or semaglutide at the same level of dosing tolerability, with a meaningfully different side-effect profile. Phase 2 data published in NEJM in 2023 reported up to 17.5% mean weight loss at 24 weeks. TRIUMPH-4 in December 2025 reported 28.7% mean weight loss at 68 weeks on the 12 mg weekly dose, plus 75% pain-score reduction in adults with knee osteoarthritis. The TRIUMPH-4 number compares favorably with tirzepatide's 22.5% at 15 mg in SURMOUNT-1 and Wegovy 2.4 mg's 14.9% in STEP 1 — though the trial populations and durations aren't perfectly comparable.

The distinct piece of retatrutide's pharmacology is the glucagon arm. Glucagon-receptor activation raises resting energy expenditure on top of the appetite suppression — meaning your body burns more calories at rest while you're also eating less. The math compounds. It's also why retatrutide tends to feel different to be on than tirzepatide does: the same caloric deficit hits a wider energy gap, and patients sometimes report fatigue and lean-mass loss alongside the substantial weight reduction. (We covered the retatrutide fatigue question in detail at #glp1-fatigue-retatrutide).

If TRIUMPH-1 confirms the 25%+ weight-loss range in adults without diabetes, retatrutide arrives as the most efficacious obesity peptide approved to date. That's the bull case for waiting.

The TRIUMPH-1 topline released May 21, 2026 is the registrational readout that anchors the NDA filing. In 2,339 adults with obesity or overweight and at least one weight-related comorbidity without diabetes, retatrutide produced 28.3% mean weight loss at 12 mg, 25.9% at 9 mg, and 19.0% at 4 mg over 80 weeks of treatment versus 2.2% on placebo. All three doses met the primary and key secondary endpoints. 45.3% of participants on 12 mg reached ≥30% weight loss — the level long associated with bariatric surgery outcomes. A 104-week extension in adults with baseline BMI ≥35 pushed mean weight loss to 30.3% (85.0 lbs) on 12 mg dosing.

The hepatic-enzyme signal that surfaced in TRIUMPH-4 (December 2025) reappeared in TRIUMPH-1 as transient ALT elevations in a subset of participants on 9 mg and 12 mg dosing, normalizing by week 24. None of the cases met DILI Hy's Law criteria; discontinuation specifically due to enzyme elevations stayed low. Liver fat dropped >80% on 8-12 mg dosing — confirming the interpretation that the transient transaminitis reflects hepatic triglyceride mobilization rather than hepatotoxicity. Discontinuation rates from all adverse events ran 4.1%, 6.9%, and 11.3% across 4, 9, and 12 mg arms versus 4.9% on placebo. The 12 mg discontinuation rate at 11.3% sits modestly above tirzepatide 15 mg in SURMOUNT-1 (~7%) and Wegovy 2.4 mg in STEP 1 (~6.5%) — a tolerability gap that prescribers and patients will weigh against the efficacy gain.

For context on the hepatic-enzyme story: semaglutide hasn't produced a meaningful hepatic-enzyme signal across its development program; tirzepatide has produced occasional elevations but not at rates that affected the label. Retatrutide's glucagon-receptor activation drives hepatic fatty-acid oxidation, which mechanistically explains why a transient hepatic-enzyme response appears — the liver is doing more metabolic work on the drug. The clinical question is whether the signal stays mild and reversible at scale (likely, based on TRIUMPH-1 confirming TRIUMPH-4 pattern) or whether one in a few thousand patients develops something more substantial (possible but not yet documented).

The practical implication: if you start retatrutide eventually, expect your prescriber to order baseline ALT/AST plus a recheck at 12 and 24 weeks, then every 6 months. That's the monitoring rhythm Lilly used in TRIUMPH-4 and TRIUMPH-1.

TRIUMPH-1 has delivered. The two registrational reads still pending are TRIUMPH-2 and TRIUMPH-3, both expected later in 2026.

TRIUMPH-2 is the obesity-plus-T2D trial: roughly 1,500 adults with BMI ≥27 and inadequately controlled type 2 diabetes (HbA1c 7.0-10.5%), randomized to retatrutide 4 mg, 9 mg, 12 mg, semaglutide 1 mg as active comparator, or placebo. Primary endpoint: HbA1c change at week 52. Co-primary: percentage weight loss. The active-comparator arm matters — this is the trial where retatrutide formally has to beat semaglutide on HbA1c (the gold-standard diabetes endpoint), not just on weight loss. TRANSCEND T2D1 disclosed on Lilly's April 30 Q1 call already showed A1c down 1.7-2.0 percentage points and 25-37 lb mean weight loss in T2D — strong Phase 3 evidence that TRIUMPH-2 will confirm the HbA1c superiority over semaglutide.

TRIUMPH-3 is the obesity-plus-cardiovascular-disease trial. Patients have established CVD or BMI ≥27 with multiple cardiovascular risk factors. The trial isn't powered for cardiovascular outcomes (the much-larger 10,000-patient TRIUMPH-OUTCOMES trial reading out 2027 handles that), but it gives Lilly the secondary-population evidence to support the cardiovascular labeling claim if and when TRIUMPH-OUTCOMES delivers.

What counts as successful readouts: TRIUMPH-2 needs to beat semaglutide on HbA1c (probably by 0.3-0.5 percentage points based on TRANSCEND T2D1) plus show meaningful weight loss. TRIUMPH-3 needs to confirm the TRIUMPH-1 weight-loss profile in a higher-cardiovascular-risk population without a fresh safety signal. Both bars look achievable based on the data through TRIUMPH-1.

Lilly will file an NDA in Q4 2026 or Q1 2027 after both readouts. FDA review with priority designation runs 6-8 months. Realistic FDA approval: mid-to-late 2027. Realistic commercial launch: Q4 2027 or Q1 2028. The TRIUMPH-1 readout has now eliminated the largest single source of risk in the program (the registrational obesity-without-T2D outcome) — the path from here to approval is execution risk, not efficacy risk.

Here's where the 'should I wait' question gets harder. Even if retatrutide approves on schedule in mid-2027, the patient-access infrastructure that exists for Wegovy and Zepbound today won't exist for retatrutide for at least 12-24 months post-approval. The pattern from Wegovy (June 2021 approval) and Zepbound (November 2023 approval): list price launched at $1,300-$1,400/month, commercial insurance coverage was patchy for the first year, Medicare excluded weight-loss-only prescriptions entirely, and savings-card programs that brought the effective patient cost down to $25-$500/month took 12-24 months to fully scale.

For retatrutide, expect:

Launch list price: $1,500-$2,000/month. Possibly higher given the additional efficacy story. Lilly's $4.5B Lebanon Indiana manufacturing investment announced May 6 targets retatrutide capacity but doesn't change the list-price math.

Commercial insurance coverage in 2027-2028: patchy. Step therapy through Wegovy or Zepbound likely required first for most plans. Plans will want to see the patient fail or insufficiently respond to a current-generation GLP-1 before approving retatrutide.

Medicare in 2027-2028: probably excluded for weight-loss-only prescriptions unless the Bridge program is extended (current sunset December 31, 2027). Cardiovascular indication labeling could open Part D coverage if Lilly files for it post-TRIUMPH-OUTCOMES — but that trial doesn't read out until 2027 at earliest.

LillyDirect cash-pay: probably $799-$999/month at launch based on the Zepbound and Foundayo precedents.

Savings card programs: $25-$50/month for commercially insured patients within 6-12 months of launch. Manufacturer copay assistance scales with PBM-coverage negotiations.

For a patient who could be paying $25/month for Wegovy or Zepbound today through a commercial insurance + savings card stack, waiting 18-24 months for retatrutide to land probably means paying $499-$999/month cash pay during the early-access window, or going through step therapy that effectively makes you take Wegovy or Zepbound first anyway. The economics of waiting are worse than they look on the surface.

Here's the calculation that doesn't get done in the patient-facing coverage. If you start Wegovy or Zepbound today (May 2026) and stick with the protocol, you'll have lost 15-22% of your body weight by November 2027 — when retatrutide approves. If you wait for retatrutide instead, you'll have lost roughly 0% by November 2027 (assuming the typical 1-3% annual gain in untreated obesity). The retatrutide weight loss between approval and 18 months on therapy (mid-2029) could be 22-29% from your November-2027 baseline.

Do the math on actual ending body weight: start at 95 kg (BMI 34 for a 5'5" woman). Wegovy starting today: by mid-2029 you're at 81 kg. Wait for retatrutide: by mid-2029 you're at 95 × 0.97^3 × (1-0.25) = 71 kg. The retatrutide path produces 10 kg more weight loss over the same time window — but it requires you to be on therapy 18-24 months later.

What that 18-24 months costs is the cardiovascular and metabolic risk reduction you don't get during the gap. The SELECT cardiovascular outcomes trial showed 20% MACE reduction on semaglutide over a median 39-month follow-up — meaning the per-month MACE-reduction benefit on Wegovy is about 0.5% per month. Waiting 18 months for retatrutide costs you roughly 9% of cumulative MACE-reduction benefit. For a 55-year-old with established cardiovascular disease, that gap is the difference between roughly avoiding a heart attack and roughly having one.

The other cost: the metabolic-set-point shift that comes from sustained weight loss. Patients who maintain 10%+ weight loss for 12-18 months see substantial improvements in insulin sensitivity, NAFLD/MASH biomarkers, and obstructive sleep apnea severity that persist even after some weight regain. Starting later means missing that consolidation window.

A patient who's young, healthy, and at a relatively low BMI can probably afford to wait. A patient with diabetes, cardiovascular disease, NAFLD, OSA, or any of the comorbidities that drive most of obesity's mortality cost cannot.

A few scenarios where holding off and starting on retatrutide is the reasonable call:

You've already failed or strongly disliked the current generation. Some patients can't tolerate Wegovy or Zepbound at therapeutic doses — usually because of persistent GI side effects, severe early weight loss that triggers gallbladder issues, or psychiatric side effects (low mood, anhedonia). For these patients, retatrutide's different mechanism may or may not be better tolerated; you won't know until you try it. But starting another semaglutide course isn't the right answer if semaglutide didn't work the first time. Wait for retatrutide and try the different molecule.

You're in the trial-eligible population and willing to enroll. Some TRIUMPH-program sites are still enrolling for the cardiovascular outcomes trial (TRIUMPH-OUTCOMES) and for the sleep apnea, MASLD, and cardiovascular-disease-specific trials. Trial participation gets you access to active retatrutide at no cost, with the trade-off of a possible placebo arm. For a patient with one of the qualifying comorbidities and acceptable risk tolerance, this is the cleanest path to retatrutide.

You're on Foundayo and waiting for the oral retatrutide formulation. Lilly hasn't publicly committed to an oral retatrutide program, but the precedent from orforglipron (oral GLP-1) and the broader oral-peptide platform investment suggests oral retatrutide is plausible in the early 2030s. If you specifically need oral therapy and the current oral GLP-1 options (Foundayo, Wegovy pill) aren't working for you, waiting is more defensible — though the wait may be 3-5 years.

You have severe obesity and want maximum efficacy from day one. A patient with BMI 50+ or with severe metabolic complications may reasonably want to go straight to the most-efficacious agent. The trade-off: you accept the access friction in 2027-2028 and probably pay $799-$999/month cash for the first 12-18 months in exchange for the additional 5-8% absolute weight loss versus tirzepatide. For some patients this calculus works. For most it doesn't.

You're in a clinical trial setting where switching is hard. Hospital-based weight-management programs and bariatric surgery practices sometimes have institutional protocols that make mid-treatment switching difficult. If you're in one of these structures, starting on the new molecule when it arrives rather than switching mid-treatment may be operationally cleaner.

Pull back. The 'should I wait for retatrutide' question is really the perennial question in obesity therapeutics: should I take the drug that's available now or the one that's coming next? It came up in 2023 when Zepbound was approaching approval and patients were on Wegovy. It came up in 2026 with Foundayo and the oral options. It will come up again in 2028-2029 when CagriSema, the petrelintide + enicepatide combination, and the AstraZeneca ASCEND triple-mechanism program approach commercial launch.

The pattern: each next-generation drug arrives with modestly better efficacy than its predecessor, at materially higher cost during the first 12-18 months of launch, and with the same tolerability and persistence-of-care problems that have defined the GLP-1 era. The drugs that exist today are remarkable. The drugs coming next year are slightly more remarkable. The drugs coming in 2028 will be slightly more remarkable still.

For most patients, the right answer is: start the best drug available today, get the metabolic and cardiovascular benefits that compound over time, and switch to a better drug when one is available, your insurance covers it, and your prescriber thinks the switch is worth it. The maintenance and switch infrastructure documented in the May 12 SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN publications is finally credible for that transition.

The single biggest mistake patients make in this space is treating obesity-pharmacology as a one-shot decision. It's a chronic-disease management framework. You'll probably try two or three drugs over the next decade. Pick the one that's available now, that you can access, and that your prescriber thinks fits your situation. Worry less about timing the next-generation transition; worry more about staying on something effective long enough to see the body-composition and cardiovascular benefits compound.

The Wegovy and Zepbound you can start today are very, very good drugs. The retatrutide you might be able to start in 2028 will be modestly better. The cardiovascular-disease, NAFLD, sleep-apnea, and metabolic-syndrome risk you accumulate between now and then is the actual cost. Most patients are better off paying the price of being on a good drug now than the price of waiting for a better one.